Table 1.
Characteristics of the included cohort studies.
| References | Country | Design | Patient characteristics | Sample size | Mean age | Male | Patient with previous VTE | Patient with unprovoked PE | Patient selection for CTEPH | Primary test for CTEPH | Follow-up duration | Number of patient with CTEPH |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Years | % | Years | ||||||||||
| Pengo et al. (11) | Italy | PC | Acute PE survivors without major comorbidity | 305 | 61.1 | 40.2 | 82 | 113 | Symptomatic patients | TTE | 7.8 | 18 |
| Becattini et al. (12) | Italy | PC | Acute PE survivors without major comorbidity | 259 | 61 | 44 | 0 | 135 | Symptomatic patients | TTE | 3.8 | 2 |
| Miniati et al. (13) | Italy | PC | Consecutive acute PE patients | 320 | 72.1 | 38.6 | 114 | NR | Patients with persistent pulmonary perfusion defects | TTE | 2.1 | 4 |
| Martí et al. (15) | Spain | PC | Acute PE survivors without major comorbidity | 110 | NR | 43.6 | 12 | 53 | All patients | TTE | 2 | 10 |
| Klok (14) | The Netherlands | PC | Consecutive acute PE patients | 866 | 55 | 47 | 195 | 308 | All patients | TTE | 2.8 | 4 |
| Poli et al. (16) | Italy | PC | Acute PE survivors without major comorbidity | 239 | 59 | 49.4 | 0 | 161 | Symptomatic patients | TTE | 3 | 1 |
| Surie et al. (17) | The Netherlands | PC | Acute PE survivors without major comorbidity | 110 | 56 | 45 | 17 | NR | Symptomatic patients | TTE | 3 | 3 |
| Berghaus et al. (18) | Germany | RC | Acute PE survivors without major comorbidity | 43 | 54.4 | NR | 43 | NR | All patients | TTE | 2 | 5 |
| Giuliani et al. (19) | Italy | RC | Acute PE survivors without major comorbidity | 111 | 65 | 41 | NR | NR | All patients | TTE | 1.8 | 5 |
| Held et al. (21) | Germany | PC | Acute PE survivors | 130 | 65.7 | 42.3 | NR | NR | Symptomatic patients | TTE | 2.2 | 8 |
| Guérin et al. (20) | France | PC | Acute PE survivors without major comorbidity | 146 | 61 | 41 | 35 | NR | All patients | TTE | 2.2 | 7 |
| Kayaalp et al. (22) | Turkey | PC | Acute PE survivors without major comorbidity | 99 | 60 | 44.4 | 1 | 36 | All patients | TTE | 1.5 | 5 |
| Yang et al. (24) | China | PC | Acute PE survivors | 614 | 61.5 | 48.5 | 0 | 204 | All patients | TTE | 3.3 | 10 |
| Klok et al. (23) | Germany | PC | Acute PE survivors | 134 | 63 | 56 | 34 | 76 | All patients | TTE | 2.5 | 6 |
| Vavera et al. (25) | Czech | PC | Acute PE survivors | 97 | 57.9 | 50 | 0 | NA | Symptomatic patients | V/Q lung scan | 2 | 4 |
| Xi et al. (26) | China | PC | Acute PE survivors | 214 | 61 | 45 | 0 | 100 | Symptomatic patients | TTE | 2.6 | 16 |
| Xu et al. (27) | China | PC | Acute PE survivors | 129 | 60 | 44.2 | 22 | 29 | Symptomatic | TTE | 2.2 | 9 |
| Pesavento et al. (28) | Italy | PC | Acute PE survivors without major comorbidity | 647 | 67 | 49.1 | 0 | 404 | Symptomatic patients | TTE | 3 | 11 |
| Coquoz et al. (29) | Switzerland | PC | Acute PE survivors | 508 | 61.2 | 53.3 | 144 | 227 | Symptomatic patients | TTE | 2 | 4 |
| Puengpapat and Pirompanich (30) | Thailand | RC | Acute PE survivors | 236 | NR | NR | 48 | NR | Symptomatic patients | V/Q lung scan | 3 | 12 |
| Hsu et al. (31) | China | RC | Acute PE survivors | 200 | 63.8 | 41.5 | 12 | 151 | Symptomatic patients | TTE | 3.8 | 8 |
| Rashidi et al. (32) | Iran | PC | Acute PE survivors | 317 | 56.5 | 51.3 | 0 | 21 | Symptomatic patients | TTE | 1 | 22 |
VTE, thromboembolism events; PE, pulmonary embolism; CTEPH, chronic thromboembolic pulmonary hypertension; RC, retrospective cohort; PC, prospective cohort; NR, not reported; TTE, Transthoracic echocardiography; V/Q, ventilation-perfusion.